Quantcast

Latest Crohn's disease Stories

2014-06-16 12:29:02

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO((TM) )(vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). "We understand how a great need still exists for additional treatment options...

2014-05-26 11:13:00

UT Southwestern Medical Center A microRNA cluster believed to be important for suppressing colon cancer has been found to play a critical role in wound healing in the intestine, UT Southwestern cancer researchers have found. The findings, first discovered in mice and later reproduced in human cells, could provide a fresh avenue for investigating chronic digestive diseases and for potentially repairing damage in these and other disease or injury settings. "We identified a novel role...

2014-05-21 23:08:04

ReportsnReports.com adds “Crohn’s Disease Drug Market and Pipeline Analysis” report to its research store. Dallas, Texas (PRWEB) May 21, 2014 Under the umbrella of inflammatory bowel diseases, Crohn’s disease and ulcerative colitis are two most common disorders. Though both these disorders have similar symptoms, the difference arises in the areas affected in the gastrointestinal tract (GI tract). The Crohn’s disease in most cases affects the end of the small bowel (the ileum)...

2014-05-20 20:22:08

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio((TM)) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). ( ) "Entyvio is a new option that...

2014-05-19 12:31:13

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Needhttp://www.reportbuyer.com/pharma_healthcare/treatments/gastrointestinal_therapeutics_asia_pacific_markets_2019_strong_potential_pipeline_biologics_account_high_regional_unmet_need.htmlGastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong...

2014-05-15 16:27:54

NEW YORK, May, 15, 2014 /PRNewswire-USNewswire/ -- In an effort to increase their long-standing commitment of improving the lives of those with inflammatory bowel disease (IBD), the Crohn's & Colitis Foundation of America (CCFA) will host the first U.S. IBD2020 meeting from May 16(th)- May 18(th) in New Orleans, LA. http://photos.prnewswire.com/prnvar/20140515/88144 "IBD2020 USA is a critical meeting of some of the brightest minds who are thinking about both IBD and Quality of...

2014-05-14 08:28:16

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_5eu_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-08 09:51:38

Old data can be mined to find new genetic associations and gene interactions The power of genome-wide association studies (GWAS) to detect genetic influences on human disease can be substantially increased using a statistical testing framework reported in the May issue of the journal GENETICS. Despite the proliferation of GWAS, the associations found so far have largely failed to account for the known effects of genes on complex disease — the problem of "missing heritability."...

2014-05-05 20:24:20

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expirieshttp://www.reportbuyer.com/pharma_healthcare/treatments/gastrointestinal_therapeutics_major_developed_markets_2019_new_drug_approvals_promising_pipeline_counter_declines_patent_expiries.htmlGastrointestinal Therapeutics in Major Developed Markets to...

2014-05-05 08:30:08

- The long-term safety profile was consistent with pivotal trials of Cimzia® ATLANTA, May 5, 2014 /PRNewswire/ -- UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia(®) (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. Remission was also assessed over the trial period. Results were presented at Digestive Disease Week (DDW), taking place in Chicago from May 3-6. "The...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related